CTOs on the Move

Complexa Inc

www.complexarx.com

 
Complexa is a clinical stage biopharmaceutical company focused on transforming the treatment of fibrosis and inflammation-associated orphan diseases. Leveraging its differentiated endogenous nitrated fatty acid cell signaling technology, Complexa is advancing a platform of agents which target fibrosis and inflammation across multiple orphan disease indications.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.complexarx.com
  • 170 North Radnor Chester Road Suite 350
    Radnor, PA USA
  • Phone: 323.602.1096

Executives

Name Title Contact Details

Funding

Complexa Inc raised $62M on 07/26/2017

Similar Companies

Proteus Biomedical

Proteus Biomedical is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Taylor Technology

Taylor Technology is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NexBio

NexBio, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intarcia

We operate with a “No Analog” mindset—continually pushing boundaries, navigating new terrain and unleashing fresh thinking. We are committed to seeking better outcomes which compels us to ask questions that have not been asked before or remain unresolved. We are driven by a desire to create meaningful impact across business, health and society to ease the burden on people living with chronic diseases. Intarcia is a rapidly emerging biotech company dedicated to redesigning the treatment, prevention and experience of chronic disease. Our cross-disciplinary teams include forward-thinking scientists and entrepreneurs collaborating in a fast-paced environment redefining the future of medicine.

IO Biotech

IO Biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. Our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase. IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.